Pregabalin for the Management of Neuropathic Pain in Spinal Cord Injury

• Mantegazza M , CuriaG, BiaginiG, RagsdaleDS, AvoliM. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol.9 , 413–424 (2010).
   PubMed Web of Science ®Google Scholar
• Tuchman M , BarrettJA, DonevanS, HedbergTG, TaylorCP. Central sensitization and Ca(V) α2δ ligands in chronic pain syndromes: pathologic processes and pharmacologic effect. J. Pain11(12) , 1241–1249 (2010).
   PubMed Web of Science ®Google Scholar
• Tzellos TG , PapazisisG, AmanitiE, KouvelasD. Efficacy of pregabalin and gabapentin for neuropathic pain in spinal cord injury: an evidence-based evaluation of the literature. Eur. J. Pharmacol.64(9) , 851–858 (2008).
   Web of Science ®Google Scholar
• Mackey C . The anticonvulsants market. Natl Rev. Drug Discov.9 , 265–266 (2010).
   PubMed Web of Science ®Google Scholar
• Ohta H , HiroshiO, ChieU, MasayukiO. A randomized, double-blind, multicenter, placebo-controlled Phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia. Arthritis Res. Ther.14(5) , R217 (2012).
   PubMed Web of Science ®Google Scholar
• Shneker BF , McAuleyJW. Pregabalin: a new neuromodulator with broad therapeutic indications. Ann. Pharmacother.39 , 2029–2037(2005).
   PubMed Web of Science ®Google Scholar
• Stahl SM . Mechanism of action of α2-δ ligands: voltage sensitive calcium channel (VSCC) modulators. J. Clin. Psychiatry65(8) , 1033–1034 (2004).
   PubMed Web of Science ®Google Scholar
• Strawn JR , GeraciotiTD Jr. The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic. Neuropsychiatr. Dis. Treat.3(2) , 237–243 (2007).
   PubMedGoogle Scholar
• Busch J , StrandJ, PosvarE et al. Pregabalin multiple-dose pharmacokinetics and safety/tolerance in healthy volunteers. Pharm. Sci. 1 , 2033 (1999).
   Google Scholar
• Widerström-Noga E , PattanyPM, Cruz-AlmeidaY et al. Metabolite concentrations in the anterior cingulate cortex predict high neuropathic pain impact after spinal cord injury. Pain 154(2) , 204–212 (2013).
   PubMed Web of Science ®Google Scholar
• Harris RE , HugginsJP, PauerL et al. Pregabalin reduces posterior insula combined glutamage and glutamine in fibromyalgia (abstract). Arthritis Rheum. 63(Suppl. 10) , 971 (2011).
   PubMedGoogle Scholar
• Bockbrader HN , RadulovicLL, StrandJC et al. Regional differences in the colonic absorption of pregabalin. Pharm Sci. 2 , 2080 (2000).
   Google Scholar
• Bockbrader HN , WescheD, MillerR et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin. Pharmacokinet. 49(10) , 661–669 (2010).
   PubMed Web of Science ®Google Scholar
• Bockbrader HN , RadulovicLL, PosvarEL et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J. Clin. Pharmacol. 50(8) , 941–950 (2010).
   PubMed Web of Science ®Google Scholar
• Randinitis EJ , PosvarEL, AlveyCW et al. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J. Clin. Pharmacol. 43(3) , 277–283 (2003).
   PubMed Web of Science ®Google Scholar
• Siddall PJ , CousinsMJ, OtteA, GriesingT, ChambersR, MurphyTK. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology67(10) , 1792–1800 (2006).
   PubMed Web of Science ®Google Scholar
• Cardenas DD , NieshoffEC, SudaK et al. A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury. Neurology 80(6) , 533–539 (2013).
   PubMed Web of Science ®Google Scholar
• Vranken JH , DijkgraafMG, KruisMR, van der Vegt MH, Hollmann MW, Heesen M. Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain136(1–2) , 150–157 (2008).
   PubMed Web of Science ®Google Scholar
• Finnerup NB , JensenTS. Clinical use of pregabalin in the management of central neuropathic pain. Neuropsychiatr. Dis. Treat.3(6) , 885–891 (2007).
   PubMedGoogle Scholar
• Gore M , FinnerupN, SadoskyA et al. Pain-related pharmacotherapy, healthcare resource use and costs in spinal cord injury patients prescribed pregabalin. Spinal Cord 51(2) , 126–133 (2013).
   PubMed Web of Science ®Google Scholar
• Westermann A , KrumovaEK, PennekampW, HorchC, BaronR, MaierC. Different underlying pain mechanisms despite identical pain characteristics: a case report of a patient with spinal cord injury. Pain153(7) , 1537–1540 (2012).
   PubMed Web of Science ®Google Scholar
• Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: placement of pregabalin into schedule V. Final rule. Fed. Register70(144) , 43633–43635 (2005).
   PubMedGoogle Scholar
• Moore RA , StraubeS, WiffenPJ, DerryS, McQuayHJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst. Rev.3 , CD007076 (2009).
   PubMed Web of Science ®Google Scholar
• Ogawa S , SatohJ, ArakawaA, YoshiyamaT, SuzukiM. Pregabalin treatment for peripheral neuropathic pain: a review of safety data from randomized controlled trials conducted in Japan and in the west. Drug Saf.35(10) , 793–806 (2012).
   PubMed Web of Science ®Google Scholar
• Freeman R , Durso-DecruzE, EmirB. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care31 , 1448–1454 (2008).
   PubMed Web of Science ®Google Scholar
• Cabrera J , EmirB, DillD et al. Characterizing and understanding body weight patterns in patients treated with pregabalin. Curr. Med. Res. Opin. 6 , 1027–1037 (2012).
   Google Scholar
• Murphy N , MocklerM, RyderM, LedwidgeM, McDonaldK. Decompensation of chronic heart failure associated with pregabalin in patients with neuropathic pain. J. Card. Fail.13(3) , 227–229 (2007).
   PubMed Web of Science ®Google Scholar
• Page RL 2nd, Cantu M, Lindenfeld J, Hergott LJ, Lowes BD. Possible heart failure exacerbation associated with pregabalin: case discussion and literature review. J. Cardiovasc. Med.9(9) , 922–925 (2008).
   Google Scholar
• de Smedt RH , JaarsmaT, van den Broek SA, Haaijer-Ruskamp FM. Decompensation of chronic heart failure associated with pregabalin in a 73-year-old patient with postherpetic neuralgia: a case report. Br. J. Clin. Pharmacol.66(2) , 327–328 (2008).
   PubMed Web of Science ®Google Scholar
• Brodie MJ , WilsonEA, WescheDL et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 46(9) , 1407–1413 (2005).
   PubMed Web of Science ®Google Scholar
• Bender G , FlorianJA Jr, Bramwell S et al. Pharmacokinetic–pharmacodynamic analysis of the static allodynia response to pregabalin and sildenafil in a rat model of neuropathic pain. J. Pharmacol. Exp. Ther.334(2) , 599–608 (2010).
   PubMed Web of Science ®Google Scholar
• Christoph T , de Vry J, Schiene K, Tallarida RJ, Tzschentke TM. Synergistic antihypersensitive effects of pregabalin and tapentadol in a rat model of neuropathic pain. Eur. J. Pharmacol.666(1–3) , 72–79 (2011).
   PubMed Web of Science ®Google Scholar
• Luszczki JJ , Florek-ŁuszczkiM. Synergistic interaction of pregabalin with the synthetic cannabinoid WIN 55, 212–212 mesylate in the hot-plate test in mice: an isobolographic analysis. Pharmacol. Rep.64 , 723–732 (2012).
   PubMed Web of Science ®Google Scholar

▪ Websites

• FDA approves Lyrica® for the management of neuropathic pain associated with spinal cord injury based on priority review. http://press.pfizer.com/press-release/fda-approves-lyrica-management-neuropathic-pain-associated-spinal-cord-injury-based-pr
   Google Scholar
• Lyrica US physician prescribing information. http://labeling.pfizer.com/ShowLabeling.aspx?id=561
   Google Scholar